Latest Commercialisation News

Page 10 of 239
Rimfire Pacific Mining’s latest Murga tests continue to show atmospheric scandium recovery, while a $2.3 million placement funds drilling and technical work across its NSW portfolio. The results remain early-stage, with projected long-term recoveries based on extrapolation rather than completed testing.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Skin Elements has secured firm commitments for a A$700,000 placement to fund working capital and commercialisation across its natural biotechnology portfolio. The raising includes 318.2 million free-attaching options, making shareholder approval and future dilution important next steps.
Ada Torres
Ada Torres
27 Oct 2026
Botanix’s Sofdra prescriptions rose 5.3% in the September quarter, but flat net revenue and a sharp cash decline have forced a major reset. The company is targeting a roughly 50% reduction in operating expenses while assessing licensing, acquisitions and broader strategic transactions.
Victor Sage
Victor Sage
27 Oct 2026
Rhythm Biosciences has widened access to its ColoSTAT blood test, lifted quarterly revenue 64% and advanced reimbursement and NHS evaluation work. The progress sits alongside A$1.803 million in cash and an estimated 1.22 quarters of funding at the current operating burn.
Ada Torres
Ada Torres
27 Oct 2026
Wide Open Agriculture has extended Univar Solutions China’s exclusive distribution rights for its lupin protein products through 2028, preserving a route into the mainland Chinese market. But the agreement is not a purchase order: revenue depends first on WOA restoring commercial supply through contract manufacturing.
Victor Sage
Victor Sage
27 Oct 2026
Argent BioPharma has granted Thai Phytomed International exclusive global commercialisation rights to four cannabis genotypes under a 10-year agreement. The deal preserves Argent’s ownership, but royalties depend on TPI generating profitable sales and securing approvals across multiple markets.
Victor Sage
Victor Sage
27 Oct 2026
Firebird Metals has improved the packing density, particle morphology and impurity profile of its lithium-manganese-rich precursor material, with tap density reaching 1.35 g/cm³ and sulphur falling 46% to 610 ppm. The results strengthen the technical case for the platform, but downstream cathode testing and larger-scale validation remain ahead.
Victor Sage
Victor Sage
26 Oct 2026
EMVision Medical Devices has taken its pivotal emu™ trial beyond 230 participants while preparing to add acute ischaemic stroke detection to the FDA validation program. The ASX-listed medtech ended September with $18.1 million in cash and $3.7 million in remaining grant funding.
Victor Sage
Victor Sage
26 Oct 2026
Metallium has signed a non-binding MOU with global commodity trader Traxys to explore feedstock, processing, offtake and financing opportunities for U.S. critical metals. The framework could improve the path to commercial scale, but it contains no binding volumes, prices, funding or sales commitments.
Victor Sage
Victor Sage
26 Oct 2026
Condor Energy has completed an independent development study for its 1 Tcf Piedra Redonda gas project and received formal qualification to negotiate a proposed offshore Peru licence. The company ended the September quarter with A$2.945 million in cash and estimated funding of 6.62 quarters.
Victor Sage
Victor Sage
26 Oct 2026
Structural Monitoring Systems remained profitable in the September quarter, but revenue, earnings and free cash flow all fell as aircraft maintenance delays weighed on avionics sales. The company also said Boeing’s FAA approval pathway for its 737NG structural monitoring application is taking longer than expected, with no revised completion date.
Victor Sage
Victor Sage
26 Oct 2026
Anatara Lifesciences narrowed its FY2026 loss and ended the year with A$470,917 in cash, but warned that further capital raising is included in its business plan and may be necessary to remain a going concern. Its AOC anti-obesity candidate produced statistically significant results in mice, while mechanism-of-action data remained inconclusive and development was placed on hold.
Victor Sage
Victor Sage
23 Oct 2026

Browse the archive

Full archive